Cyclophosphamide + GVAX Pancreas Vaccine (GVAX) + Pembrolizumab + IMC-CS4
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pancreatic Cancer
Conditions
Pancreatic Cancer
Trial Timeline
Sep 27, 2018 → Aug 29, 2023
NCT ID
NCT03153410About Cyclophosphamide + GVAX Pancreas Vaccine (GVAX) + Pembrolizumab + IMC-CS4
Cyclophosphamide + GVAX Pancreas Vaccine (GVAX) + Pembrolizumab + IMC-CS4 is a phase 1 stage product being developed by Eli Lilly for Pancreatic Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT03153410. Target conditions include Pancreatic Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03153410 | Phase 1 | Completed |
Competing Products
20 competing products in Pancreatic Cancer